Dice CEO: Energy, T...
Health Care: Health Services
Enzo Biochem Inc. (ENZ: NYSE)
$1.79 -0.03 | -1.65%
06/01/12 - 04:03 PM ET
Company Cash Flow
| Jul 2011 | Jul 2010 | Jul 2009 | Jul 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -12.96M | -22.23M | 23.56M | -10.65M |
| Operating Gains/Losses | -131.00K | 463.00K | 697.00K | -313.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -6.54M | -3.84M | -1.41M | -2.84M |
| (Increase) Decrease in Inventories | -178.00K | -663.00K | 2.27M | 1.01M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 1.46M | 2.35M | -571.00K | -1.06M |
| (Decrease) Increase In Other Current Liabilities | -174.00K | -310.00K | 322.00K | -1.26M |
| (Increase) Decrease In Other Working Capital | 6.00K | 90.00K | 0.00 | 0.00 |
| Other Non-Cash Items | 6.13M | 6.24M | -40.02M | 5.62M |
| Net Cash From Continuing Operations | -8.33M | -13.46M | -11.48M | -8.56M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -8.33M | -13.46M | -11.48M | -8.56M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 182.45M | 232.14M | 318.65M | 0.00 |
| Purchases of Property, Plant & Equipment | -1.22M | -3.25M | -2.71M | -3.23M |
| Acquisitions | 0.00 | 0.00 | -14.54M | -16.14M |
| Purchases of Short-Term Investments | -167.65M | -213.64M | -361.96M | 0.00 |
| Other Cash from Investing Activities | -45.00K | 81.00K | 384.00K | 594.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 13.54M | 15.33M | -60.17M | -18.78M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 0.00 | 0.00 | 348.00K | 470.00K |
| Repayment of Long-Term Debt | -68.00K | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | -12.00K |
| Net Cash From Financing Activities | -68.00K | 0.00 | 348.00K | 458.00K |
| Effect of Exchange Rate Changes | 257.00K | -33.00K | -92.00K | 60.00K |
| Net Change in Cash & Cash Equivalents | 5.40M | 1.83M | -71.39M | -26.83M |
Portfolios with ENZ
- Portfolio NameUser Type
- UserBarron's Insider Purchases ...
- ContributorStockerblog.com Gene Therap...
- Userkelvinenz Portfolio 1
- UserS-0022
- UserTraderSteveUK Portfolio 1
- UserRT_in_CA
- UserSo far, I'm beating the S&a...
- Userjwcarmack Portfolio 1
- Userrecentoutperform070824
- Usersfields Portfolio 1
Latest ENZ Headlines from TheStreet
- Thursday Earnings Live Blog 10.14.10 | 04:10 pm
- Investors May See Upside Down Under 09.16.10 | 08:09 am
- Enzo Biochem 1Q Loss Narrows On Revenue Boost 12.10.09 | 04:12 pm
- Enzo Biochem 4Q Loss Widens On Costs 10.14.09 | 06:10 pm
- Tuesday's Health Winners & Losers 10.16.07 | 04:10 pm
- Enzo Biochem Falls on Court Dismissal 09.07.07 | 02:09 pm
- Friday's Health Winners & Losers 09.07.07 | 02:09 pm
- Checking Up on Biotech 08.10.07 | 04:08 pm
- Monday's Health Winners & Losers 10.16.06 | 02:10 pm
- Enzo Biochem Loss Widens 10.16.06 | 11:10 am
Press Releases for ENZ
- Enzo Biochem Launch Of Test For Measuring Risk Of Colorectal Cancer Underscores Growing Role Of Molecular Diagnostics - Business Wire 04.10.12 | 08:04 am
- Enzo Biochem Presents New AmpiProbe™ Nucleic Acid Amplification Platform Details At ESCMID London Meeting - Business Wire 04.01.12 | 04:04 pm
- Enzo Biochem To Present At Needham Healthcare Conference - Business Wire 03.27.12 | 12:03 pm
- Enzo Biochem Announces Expanded Distribution Agreement With Japan’s Cosmo Bio - Business Wire 03.20.12 | 07:03 am
- Enzo Biochem’s Clinical Laboratory Applies For NY State Health Department Approval For First Assay Based On Its AmpiProbe™ Amplification Platform - Business Wire 03.13.12 | 07:03 am
- Enzo Biochem Reports Improved Second Quarter Results - Business Wire 03.12.12 | 04:03 pm
- Enzo Biochem To Present New AmpiProbe™ Nucleic Acid Amplification Platform At ESCMID London Meeting - Business Wire 03.08.12 | 08:03 am
- Enzo Biochem Schedules Teleconference To Discuss 2012 Second Quarter Results On March 13, 2012 At 8:30 AM E.T. - Business Wire 03.08.12 | 07:03 am
- Enzo Biochem Receives Approval For Novel Blood Based Test For Colorectal Cancer Risk - Business Wire 02.21.12 | 08:02 am
- Enzo Biochem To Present At 2012 Leerink Swann Global Healthcare Conference - Business Wire 02.10.12 | 12:02 pm
Partner Headlines for ENZ
- Investors Should Wait Out Quest & LabCorp - Seeking Alpha 02.16.12 | 09:02 am
- Enzo Biochem: Personalized Medicine Is More Than Targeted Therapeutics - Seeking Alpha 04.03.11 | 07:04 am
- Competitive Technologies: Short Squeeze Coming or Another Leg Down? - Seeking Alpha 08.25.10 | 09:08 am
- Top 5 Percentage Gainers On NYSE (DV, CKH, ENZ, LAD, CMG) - Benzinga 07.23.10 | 03:07 pm
- MB FINANCL INC (MBFI) - Profit Tracks - Zacks 04.13.10 | 01:04 am
- UPDATE 2-Enzo wins round in Applera patent fight - Reuters 03.26.10 | 04:03 pm
